- ;The fall from grace last week of Dr. José Baselga, the former chief scientific officer of Memorial Sloan Kettering Cancer Center, illuminated a longstanding problem of modern medicine
- Potentially corrupting payments by drug and medical device makers to influential people at research hospitals are far more common than either side publicly acknowledges.
- Dr. Baselga, a giant in cancer research whose work led to the discovery of the lifesaving drug Herceptin, resigned on Thursday after The New York Times and ProPublica reported that he had repeatedly failed to properly disclose millions in industry payments.
;;Decades of research and real world examples have shown that such entanglements can distort the practice of medicine in ways big and small. ...
- In statements to industry analysts and the American Association for Cancer Research, Dr. Baselga praised two drug trials that many of his peers considered failures, without mentioning that the trials’ sponsor, Roche, had paid him millions of dollars. He also withheld his financial conflicts from dozens of publications, including at least one journal that he edited.
- Those conflicts touched his own institution directly, in that several of the companies he advises have business with Memorial Sloan Kettering. Both Varian Medical Systems, which sells the hospital radiation equipment, and Bristol-Myers Squibb, which sells it medications, pay him several hundred thousand dollars a year for his role on their boards of directors.
- - The Editorial Board, Medicine’s Financial Contamination, NYT, Sept. 14, 2018